United Kingdom · Question · Written question
UIN 109686
Blood Cancer: Medical Treatments
Original
Introduced
29 January 2026
Last action
5 February 2026 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
5 February 2026
Summary
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact on patients with relapsed or refractory Mantle Cell Lymphoma of NICE’s draft decision not to recommend brexucabtagene autoleucel (Tecartus) for N
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
29 January 2026
Written question
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact on patients with relapsed or refractory Mantle Cell Lymphoma of NICE’s draft decision not to recommend brexucabtagene autoleucel (Tecartus) for N
Source: Commons
5 February 2026
Answer
The National Institute for Health and Care Excellence (NICE) is currently re-evaluating brexucabtagene autoleucel to determine whether it can be recommended for routine National Health Service funding following a period of managed access through the Cance...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2026-01-29/109686
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1876749
- uk · wq-1876749 · source updated 5 February 2026